PROTEON THERAPEUTICS INC (NASDAQ:PRTO) Stock Sentiment Improves to 2.5

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Corporate Logo

“Big money” Positions

In 2018 Q3 PROTEON THERAPEUTICS INC (NASDAQ:PRTO) big money sentiment increased to 2.5, SEC filings reveal. That’s up 1.64, from 2018Q2’s 0.86. 10 investment professionals started new or increased stock positions, while 4 reduced and sold their stakes in PROTEON THERAPEUTICS INC so the sentiment is better. These funds own 8.83 million shares, that’s up from 7.28 million shares in 2018Q2. Funds holding PROTEON THERAPEUTICS INC in top 10 changed to 3 from 3 for the same number . In total 1 funds closed positions, 3 reduced and 6 increased. Also 4 funds bought new PROTEON THERAPEUTICS INC stakes.

Significant PROTEON THERAPEUTICS INC Shareholders

As of 2018 Q3 Abingworth Llp has 2.28% invested in PROTEON THERAPEUTICS INC. As of 2018 Q3, 983,381 shares of PROTEON THERAPEUTICS INC are owned by Mpm Asset Management Llc. Moreover, Deer Vii & Co. Ltd. reported 315,101 shares in PROTEON THERAPEUTICS INC equivalent to 0.92% of its fund’s portfolio. The New York-based fund New Leaf Venture Partners L.L.C. have invested about 0.53% of the active investment manager’s stock portfolio in PROTEON THERAPEUTICS INC. The Massachusetts-based fund Ra Capital Management Llc looks positive on PROTEON THERAPEUTICS INC, possessing 1.34 million shares.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases.The firm is valued at $47.48 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease.Last it reported negative earnings.

Ticker’s shares touched $2.47 during the last trading session after 1.20% change.Proteon Therapeutics, Inc. is downtrending after having declined 4.86% since January 14, 2018. PRTO has 51,106 volume or 26.25% up from normal. The stock underperformed the S&P500 by 4.86%.

Proteon Therapeutics, Inc. (NASDAQ:PRTO)’s earnings report is anticipated on March, 13., as reported by RTT. Last year’s earnings per share was $-0.31, while now analysts expect change of 19.35 % up from current $-0.25 earnings per share. Wall Street forecasts 0.00 % EPS growth as of March, 13.

Renaissance Tech Ltd Liability Co invested 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Baker Bros Advisors Ltd Partnership owns 0% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 298,591 shs. Panagora Asset Mngmt Inc accumulated 10,871 shs. 315,101 were accumulated by Deer Vii. Fincl Counselors Incorporated has invested 0% of its capital in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Moreover, Ra Capital Lc has 0.14% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Royal Savings Bank Of Canada reported 3,848 shs. Raymond James Fincl Advsr Inc has 12,300 shs. New York-based New Leaf Venture Prns Lc has invested 0.53% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Abingworth Llp reported 2.02M shs or 2.28% of all its holdings. Mpm Asset Management Limited Liability Com reported 983,381 shs or 1.3% of all its holdings. New York-based Morgan Stanley has invested 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Moreover, Northern has 0% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 18,373 shs. Vanguard Grp Inc Inc invested 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Drw Securities Lc reported 0% stake.

For more Proteon Therapeutics, Inc. (NASDAQ:PRTO) news published briefly go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Seekingalpha.com or Marketwatch.com. The titles are as follows: “Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results – GlobeNewswire” published on March 14, 2018, “Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase – GlobeNewswire” on May 10, 2017, “Proteon Therapeutics to Present at Two Upcoming Investor Conferences – GlobeNewswire” with a publish date: March 06, 2018, “Reader Inquiry: Is Proteon Therapeutics Still A Buy? – Seeking Alpha” and the last “Proteon Therapeutics’ stock plummets after failed trial of kidney disease treatment – MarketWatch” with publication date: December 13, 2016.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.